March 2019- Volume 15, Issue 3

In this Issue

Business & Government Policy

Targets acquired

Targets acquired

A look at a few recent merger and acquisition deals in the pharma world

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Novartis exercises option to license AKCEA-APO(a)-LRx

Novartis exercises option to license AKCEA-APO(a)-LRx

Phase 3 planning and initiation activities underway; Akcea earns $150-million license fee

Feature

Focus Feature: Artificial Intelligence 2.0

Focus Feature: Artificial Intelligence 2.0

Artificial intelligence cannot solve every problem, but it has the potential to break up many bottlenecks

Cancer on the mind

Cancer on the mind

Glioblastoma remains a difficult cancer to treat, but the brain malignancy is seeing increasing attention in R&D

Editor's Focus

Editor’s focus: Filling the voids

Editor’s focus: Filling the voids

Looking at some of the progress in areas we had been hoping to see more from in the past, including schizophrenia, antibiotics and artificial intelligence

Contract Services

Under the tongue rather than getting the needle

Under the tongue rather than getting the needle

WuXi STA and BioLingus sign technology and marketing collaboration for sublingual delivery

Six.02 Bioservices launches

Six.02 Bioservices launches

Company intends to be a ‘new model’ for providing bioservices in protein-based R&D

UK’s Pathios signs CRO Sygnature

UK’s Pathios signs CRO Sygnature

Deal focused on development of therapies in autoimmune disease and immuno-oncology

Commentary

Guest Commentary: A tale of safety and consistency

Guest Commentary: A tale of safety and consistency

Drs. Ulrike Herbrand, Christopher Sucato and Alvaro Jorge Amor of Charles River Laboratories discuss the challenges of bringing antibody-drug conjugates to market

Out of order: Keep talking

Out of order: Keep talking

Active discussion regarding diseases and clinical trial progress is important not just for keeping hope alive and boosting awareness, it's also essential in reminding patients and their families that there are others out there who share their struggles

Preclinical

The data are in on CB 2679d-GT

The data are in on CB 2679d-GT

Catalyst Biosciences announces preclinical data on gene therapy candidate for hemophilia B

Natural killer cells promise life

Natural killer cells promise life

GT Biopharma encouraged by clinical potential of triple-threat TriKE cells in cancer

Orion reports positive results for OB-002O

Orion reports positive results for OB-002O

Investigational therapeutic for Colorectal Cancer shows promise in preclinical study

Alternative to animal testing

Alternative to animal testing

‘Human-on-a-chip’ models evaluate systemic toxicity

Paving the way

Paving the way

Shingles treatment the first of several herpesvirus drug candidates to enter IND-enabling studies

Research & Development

Dual approach to pancreatic cancer

Dual approach to pancreatic cancer

Roswell Park researchers publish two studies on progress against the disease

New options with nitrogen

New options with nitrogen

Rice University researchers describe a novel chemical synthesis approach

From single-cell to many cells

From single-cell to many cells

Researchers use RNA sequencing to investigate spermatogonial stem cells and tackle infertility

Harvard develops kidney organoid

Harvard develops kidney organoid

Method for growing kidney organoids under flow enhances their vascularization and maturation

A decline for R&D

A decline for R&D

Research & development returns fall to lowest level in nine years

Discovery

ALS hope at last?

ALS hope at last?

Small-molecule targets may prevent ALS

GWAS and new gene answers

GWAS and new gene answers

Genomic exploration by Chinese researchers uncovers new information regarding genetic schizophrenia risk

CDD gains grants

CDD gains grants

CDD awarded two SBIR grants on digital representation of chemical mixtures, deep learning strategy for drug discovery

Stem cells and screening

Stem cells and screening

Ncardia seeks to bring human disease biology earlier into drug discovery and development

Copper conflict

Copper conflict

Staphyloccocus genes offer potential pathways for overcoming antibacterial resistance

Clinical Trials

Immunotherapy before surgery?

Immunotherapy before surgery?

Trial indicates that the process shows benefit for gliobastoma patients

Mixed results

Mixed results

Companies face both trial roadblocks and progress as they tackle DMD

Nuzyra fights pneumonia

Nuzyra fights pneumonia

Drug shown safe and effective in adults with pneumonia and skin infections

Combating rejection

Combating rejection

Kamada’s Phase 2 proof-of-concept trial shows prevention of lung transplant rejection for one year

Positive data for TRC105

Positive data for TRC105

TRACON announces results from ongoing Phase 1b/2 trial in hepatocellular carcinoma

Diagnostics

‘Changing the face of genetic diagnostics’

‘Changing the face of genetic diagnostics’

Study shows Bionano’s Saphyr system accurately detects genetic disorder FSHD

Prediction precision

Prediction precision

New tool said to offer objective prostate cancer assessment

Taking it to the nose to fight lung cancer

Taking it to the nose to fight lung cancer

Veracyte announces strategic collaboration with Johnson & Johnson for development of nasal swab test

From mice to man

From mice to man

Elevated hormone flags liver problems related to methylmalonic acidemia
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2021 Issue Front Cover

Latest Issue  

• Volume 17 • Issue 11 • November 2021

November 2021

November 2021 Issue